TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02505607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overactive Bladder Care Plan counseling
Description: Use of a printed Overactive Bladder Plan of Care information sheet.
Study: NCT02922244

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Apply moisture cream to the treatment skin everyday after radiation therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cucumber cream
Description: Apply cucumber cream to the treatment skin everyday after radiation therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Centella cream
Description: Apply centella cream to the treatment skin everyday after radiation therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thunbergia cream
Description: Apply thunbergia cream to the treatment skin everyday after radiation therapy
Study: NCT02925286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prevention program for gambling in the workplace
Description: The intervention group will receive a gambling prevention program which includes generating and implementing policies and education on addiction and gambling. The full length of the program will be about 14 hours.
Study: NCT00101179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given orally
Study: NCT01863784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168
Description: All participants will receive JNJ-38518168 30 mg tablet once daily from Day 1 to Day 14.
Study: NCT00279175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of enriched bone marrow-derived progenitor cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo medium supplemented with autologous serum
Study: NCT03288532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: controlled infusion via an infusion pump into a peripheral or central vein
Study: NCT03288532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: controlled infusion via an infusion pump into a peripheral or central vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: controlled infusion via an infusion pump into a peripheral or central vein
Study: NCT04109547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Tablets to be taken once-daily for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Tablets to be taken once-daily for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Tablets to be taken once-daily for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets to be taken once-daily for 26 weeks
Study: NCT04542837

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN046
Description: Subjects enrolled in the study will be intravenously administered KN046 5mg/kg every 3 weeks (Q3W), until disease progression, or unacceptable toxicity, or withdrawal of consent, or lost to follow-up, or died, or treatment for 2 years, or the investigator decides to terminate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Subjects enrolled in the study will receive lenvatinib 12 mg (BW≥60 kg) or 8 mg (BW\<60 kg) orally once a day (QD) ,until disease progression, or unacceptable toxicity, or withdrawal of consent, or lost to follow-up, or died, or treatment for 2 years, or the investigator decides to terminate.
Study: NCT04602221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film-coated tablet
Study: NCT04218240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 200 MG capsules
Description: oral pregabalin 200 mg capsules given with a taper on day 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral tablet
Description: oral Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine 0.18Mg Tab
Description: lofexidine 0.18 tab given with a taper starting on day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine 0.18Mg Tab
Description: lofexidine 0.18 tab given with a taper starting on day 5
Study: NCT02435212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox granule formulation
Description: Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use and will be administered based on body weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox DT formulation
Description: Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use and will be administered based on body weight.
Study: NCT04602221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Film-coated tablet
Study: NCT03085043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT of the abdomen and pelvis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo pelvic MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Whole Body Diffusion-Weighted Imaging
Description: Undergo magnetic resonance whole body diffusion-weighted imaging
Study: NCT04984551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extension of Community Health (ECHO) Telementoring Clinic
Description: Participate in ECHO clinics presenting cases for guidance and feedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-Country Workshops
Description: In-Country Workshops Participate in hands-on training and workshops

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Professional Oncology Educations Programs
Description: Receive 5 core online lectures

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Medical charts are reviewed for data collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire(s)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaire(s)
Study: NCT01379898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxybenzamine
Description: Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)
Study: NCT02839096

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate

Intervention type: DRUG
Group type: OTHER
Intervention: Ferrous Sulfate
Description: Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Ferrous Sulfate
Description: Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.
Study: NCT04127604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Treatment Adherence Program for Veterans (ITAP-VA)
Description: Psychosocial support and treatment to improve treatment adherence, symptoms, and functioning.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Assessment and Follow-up Evaluation (SAFE)
Description: Measurement-based care assessment and evaluation.
Study: NCT02623972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: administered IV for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: administered IV for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: administered IV with cyclophosphamide for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: administered IV with cyclophosphamide for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: administered IV with adriamycin for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: administered IV with adriamycin for 4 cycles
Study: NCT04245150

Intervention type: OTHER
Intervention: Stool sample
Description: Stool sample

Intervention type: OTHER
Intervention: Skin Swab Sample
Description: Skin Swab Sample
Study: NCT03450161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl dosing schemes
Description: We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl dosing schemes
Description: We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl dosing schemes
Description: We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.
Study: NCT02608190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training
Description: See protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Working memory training
Description: See protocol
Study: NCT01783613

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid administration: 50 mg/kg/day during 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 50 mg/kg/day during 12 months
Study: NCT01283139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sifalimumab 200 mg
Description: Sifalimumab 200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sifalimumab 600 mg
Description: Sifalimumab 600 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sifalimumab 1,200 mg
Description: Sifalimumab 1,200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
Study: NCT04379700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization
Description: Transcatheter arterial embolization of one or more genicular artery(ies) using Embozene™ Color-Advanced Microspheres. Embozene™ Color-Advanced Microspheres are spherical, tightly calibrated, biocompatible, non-resorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer used for embolization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embozene™ Microspheres
Description: Embozene™ Microspheres are spherical, tightly calibrated, biocompatible, nonresorbable, hydrogel microspheres coated with an inorganic perfluorinated polymer (Polyzene™-F). The microspheres intended to occlude vasculature for the purpose of blocking blood flow to a target tissue. They are available in prefilled syringes in a range of sizes suitable for embolic therapy. The microspheres are compressible to enable smooth delivery through the indicated delivery catheter and color-coded by size to allow for easy identification. 250 μm microsphere will be used and are supplied in prefilled yellow syringes.
Study: NCT00004563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching gelcaps 25 mgs
Study: NCT01423500

Intervention type: DRUG
Group type: OTHER
Intervention: VP16
Description: patients with MSD receive as conditioning VP16 60mg/kg/d on day -3

Intervention type: RADIATION
Group type: OTHER
Intervention: TBI
Description: patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning

Intervention type: DRUG
Group type: OTHER
Intervention: VP16, ATG
Description: patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1

Intervention type: RADIATION
Group type: OTHER
Intervention: TBI
Description: patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
Study: NCT02614417

Intervention type: OTHER
Intervention: Polysomnography
Description: One night polysomnography performed using standard techniques and scored in accordance with American Academy of Sleep Medicine standards. Polysomnography monitors sleep by electroencephalography (F4-A1, C4-M1, O2-M1 F3-M2, C3-M2, O1-A2), electro-myography (submental and tibialis anterior muscles), electro-oculography, nasal flow, respiratory effort, pulse oximetry and transcutaneous carbon dioxide partial pressure.
Study: NCT04441060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distress intervention (CBT & Mindfulness-based program)
Description: Distress intervention is not fully developed yet, but we are working on the development of distress intervention based on CBT \& Mindfulness-based program.
Study: NCT02862834

Intervention type: GENETIC
Intervention: High-throughput exome sequencing
Study: NCT06434896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ctDNA analysis after surgery
Description: ctDNA analysis of post-surgery blood samples will be performed directly after informed consent for MEDOCC-CrEATE.
Study: NCT04901260

Intervention type: DEVICE
Intervention: AMAZE™ Disease Management Platform
Description: The disease management platform includes a patient mobile application where patients can enter daily symptoms, communicate with their healthcare providers, and access educational materials. Additionally, the healthcare providers will have access to a dashboard that is integrated with the EMR and patient app.
Study: NCT04656704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronidase injected intradermally
Description: Patients will receive 200 units of hyaluronidase injected intradermally to the cutaneous lips on Weeks 0, 4, 8, 12, and 16, and 20
Study: NCT04572113

Intervention type: DEVICE
Intervention: Cervical collar
Description: Data will be recorded while patients are not wearing or wearing one of two cervical collars

Intervention type: DEVICE
Intervention: Cervical collar
Description: Data will be recorded while patients are not wearing or wearing one of two cervical collars
Study: NCT00318071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merci Retriever
Description: For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.~Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.~Recanalization was defined as TIMI II or TIMI III per angiography.
Study: NCT02744911

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SpeechVive device
Description: The SpeechVive is a wearable device that plays multi-talker babble noise in one ear while the person wearing it is talking. The noise is voice-activated (only present when the person speaks). The noise does not interfere with the ability to hear communication partners. The noise coming from the device functions as a natural external cue for people with Parkinson's disease to talk more loudly and clearly. Treatment will involve asking the participants to wear the device daily during the treatment period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpeechVive device
Description: The SpeechVive is a wearable device that plays multi-talker babble noise in one ear while the person wearing it is talking. The noise is voice-activated (only present when the person speaks). The noise does not interfere with the ability to hear communication partners. The noise coming from the device functions as a natural external cue for people with Parkinson's disease to talk more loudly and clearly. Treatment will involve asking the participants to wear the device daily during the treatment period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine interaction
Description: Participants will interact with the speech-language pathologist using the telemedicine platform from their home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In person interaction
Description: Participants will interact with the speech-language pathologist in-person at the speech pathologist's office
Study: NCT04641871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym022
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym023
Description: IV infusion over 30 minutes on day 1 and 15 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: IV infusion over 90 min on day 1 and 15 of the first 2 cycles. After 2 cycles of treatment, irinotecan may be discontinued at the Investigator's discretion
Study: NCT02013960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytotec
Description: Cytotec medication compared with cytotec and laminaria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytotec
Description: Cytotec medication compared with cytotec and laminaria